![]() |
![]() ![]() |
![]() |
![]() |
Français | ![]() |
Government of Canada BioPortal | ||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
![]() |
![]() |
Home | ![]() |
Site Map | ![]() |
News Room | ![]() |
FAQ | ![]() |
Search | ||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() ![]()
|
![]() |
![]() ![]() ![]() ![]() ![]() Highlights of Halifax Roundtable IP/PHL
Halifax Session
April 23, 2001 Prepared by: Consultation Participants
Technical Resources Canadian Biotechnology Advisory Committee Canadian Biotechnology Secretariat Media Relations Facilitation Team Roundtable Consultation Purpose and ObjectivesThe Canadian Biotechnology Advisory Committee (CBAC) as part of its national consultation process held a roundtable in Halifax, Nova Scotia, on April 23, 2001, to address matters concerning Biotechnological Intellectual Property and Patenting of Higher Life Forms. Roundtable PurposeTo engage stakeholders in a dialogue to provide their views to CBAC on possible policy initiatives regarding Biotechnological Intellectual Property and the Patenting of Higher Life Forms. Roundtable Objectives
Issues/Topics of DiscussionThe roundtable addressed three matters: identifying issues and guiding principles; the types of higher life forms, if any, that should be patentable and subject to patent protection; and determining Canada’s international roles. Topic 1: Identifying Issues and Guiding PrinciplesQuestion A: What are the key issues that need to be understood and assessed in determining Canada’s approach to developing a policy on IP and PHL?The following issues were identified by participants: What are patents for, and who do they serve?Patents were developed more than a century ago to address perceived needs arising from the then dominant sciences of chemistry and physics. The same legislative principles are still being applied to biotechnological inventions. As living and reproducing matter, it was feared that there was a greater risk that biotechnological subject matter could escape into and affect other species and the environment. Questions were therefore raised as to whether biotechnology is appropriately protected by patent law which was originally intended for mechanical and chemical inventions. A number of questions were raised based on the premise that patents allow the protection of investments in new products, and deriving of profits.
Patenting and the development of knowledgePatents are designed to protect the commercialization of inventions for a period of twenty years to allow the inventor to recover research and development expenditures and reap the benefits of exclusivity. Patents also are intended to place new knowledge into the public domain. How does the patent process affect the development of science?Some participants raised concerns about the relative lack of publicly-funded-research and the fact that the private sector was now the main forum for research and development. The result is that ownership of patents is now more highly concentrated in the private sector. The benefits of free, non-commercial research which has a high value to society, should not be compromised by granting patent rights. Concerns were raised about the relationships between the advancement of knowledge through publicly funded research and the ownership of patent rights by companies. Awareness and public informationThe issues around patenting are of great public significance. Some participants felt that much stronger efforts are needed to bring the issues before the public for broad debate and input into the development of policies. In addition, they decried the perceived lack of transparency in the patenting processes and sought openness, promotion of awareness and public access to knowledge. They believed the ability of society to make informed choice among policy options will be dependent on a well-informed public. It is equally important that policy-makers, and adjudicators, be aware of the views of the public and the relevant facts related to policy choices. Huge gaps of understanding exist between the various players in determining public policy; scientists, policy makers, public advocacy groups, the media, the general public, all contain within each group as wide a range of opinions as there appear evident between groups. National debate is limited by expressions of the extreme positions, and by the processes of policy development that may tend to require organizational uniformity of view. As in almost any area of public policy, means of setting out the issues openly and transparently are essential. Effects of patents on genetic diversity and the environmentConcerns were expressed about increasing the concentration of corporate ownership of patents on the use of new organisms. The exclusivity that patents provide to companies in these circumstances could have the effect of decreasing genetic diversity. The following questions were discussed without resolution: Will the holding of patents enhance the use of biotechnologically derived organisms to the detriment of the natural world, and loss of components of the global gene pool (loss of identity preservation)? Might such effects decrease the development and use of natural therapies? Is a global agreement needed on the environmental implications of biotechnological applications? Question B: What are the principles that should be used to guide the development of a policy on IP and PHL?The Canadian Biotechnology Advisory Committee has identified principles to develop a useful framework for assessing proposals for public policy related to biotechnology. Comments were invited from participants on these principles. Justice: Accountability Autonomy Beneficence Respect for Diversity Knowledge Caution Specific comments on the principles were:
One breakout session suggested that the concept of respect and dignity should be extended to plants, animals and the environment. The present proposals may be at too high a plane for general appreciation, not indicating to the majority of Canadians how the balances needed in any application of ethics and values can be achieved in the practical world when conflicts between principles or values must be resolved. Some wished to place the highest priority on precaution. However, others pointed out that knowledge is never complete, and that science can never exclude all possibilities. The balance between the need for caution and the need for progress is complex. The desire to do good and do no harm was also expressed. Openness, transparency, public awareness and access to knowledge to allow society to make informed choices were given high priority in the discussions. The role of the patent system as promoter of social benefit needs further exploration. Wealth creation is a driving force behind innovation and use of the patent system. Although economic wealth is not without social value, the issue now may be to balance wealth creation through patenting with other values for society. Human rights were a major concern, specifically the rights of people in less developed regions whose traditional practices could become the subject of intellectual property and exploited by industries in developed countries without appropriate compensation or benefits-sharing. Concern was expressed about the concentration of wealth in a few hands. Exploitation also came up related to people/groups contributing tissue for gene identification and not sharing the benefits of the resulting research. The suggestion was made that under “justice” there should be a commitment to ensure that policies and practices do not contribute to the exploitation of vulnerable groups. Environmental considerations are of great importance, specifically the maintenance of genetic diversity, and promotion of sustainable development. The principles in the CBAC discussion document were considered a welcome start. Enunciation of a coherent set of values and principles is very difficult. It was agreed that Canada first needed to determine the key objectives of its public policy, based on Canadian social and ethical values. Implementation of Ethical values Participants tended to prefer a mechanism independent of the patent system for addressing social and ethical issues. Accountability must be built into the legal system. Legislation is needed to address who is responsible for adverse effects of biotechnology, whether or not these are foreseen at the time of patenting, and how. For example, where a new life form is inadvertently spread to the detriment of a person or the environment, the responsible person must be identified and held accountable. In an area as rapidly moving as biotechnology, since legislation is comparatively slow to respond, legislation should have a built-in review and renewal mechanism for patenting of biotechnology. For example, patents could be revoked for ethical reasons through the action of an independent body. Many participants suggested that Canada should adopt an “ordre public” or morality provision in its legislation. Topic 2: What should be patentable?This topic addressed the questions of whether there should be a policy to permit patenting of higher life forms for particular purposes and, if so, what factors must be considered and what safeguards and conditions are required? The range of innovations that can be patented caused concern to participants. A need was identified to make the definition of higher life forms that can be patented more precise. For example, it is not sufficient to draw the line between human and non-human life forms. The ability to patent DNA sequences was questioned. Closely related to this question is the extent to which the utility of a DNA sequence must be disclosed in an application for patentability. What are the relevant criteria? Question A: Is there a rationale for a policy allowing patenting for medical research and health care applicationsGenerally, participants were favourable to a broad acceptability of patenting of higher life forms for medical use. However, participants were well aware that patenting of life forms may be offensive to some sectors of society on moral and cultural grounds. Many participants expressed the view that the rationale for patenting for medical research and health care applications is no different than patenting for any other purpose. Participants also noted that patenting is one step, but other processes or mechanisms are also needed to monitor and regulate application and effects. Factors to be ConsideredParticipants identified a number of factors that needed to be considered and addressed in the context of patenting medical research and health care applications These are:
SafeguardsParticipants listed a number of conditions and safeguards that should constrain or set guidelines and parameters. These are:
Questions/ChallengesParticipants also identified a number of questions that must be answered and challenges to be addressed to arrive at a policy pertaining to patenting of higher life forms for these purposes.
‘Question B: Is there a Rationale for a Policy Allowing for the Patenting of Animals and Plants for Agricultural Purposes?Participants saw both benefits and disadvantages of patenting animals and plants for agricultural use. The benefits identified were:
The disadvantages are:
FactorsA number of factors that should be considered when reviewing patent applications for agricultural purposes were identified. They are:
SafeguardsThe following safeguards were proposed:
Questions/ChallengesParticipants identified questions and challenges in patenting for agricultural purposes as follows:
Question C: Is there a Rationale for the Patenting of Animals and Plants for Industrial Use?Two divergent points of view were clearly expressed. The first view is that, the Patent Act is needed to provide protection of inventions and thereby encourage innovation. The social/environmental/moral issues need to be dealt with, but outside the patenting process. The second view is that patenting should not be allowed because of unknown risk. We need to “stop the clock” while we undertake more research to have more knowledge of the benefits and risks and to have confidence to proceed. Technology may have outpaced society and social values. There was also general concern with the potential for contaminating the gene pool as plant genomes mingle and through cross-breeding over time. Biological dissemination is very difficult to reverse. FactorsRelevant factors include:
SafeguardsThe only safeguards are those that exist through the approvals and regulatory processes. It may be necessary to establish mechanisms for monitoring and review to enhance safeguards. Questions/Challenges
Topic 3: Determining Canada’s International RoleThe third break-out discussion topic addressed Canada’s international obligations and role concerning biotechnological intellectual property and the patenting of higher life forms. Patenting systems vary considerably between countries. Canada is bound by treaties to specific actions in patenting, but also has some flexibility to take its own course. In addition to addressing its own sovereign interests, participants felt that Canada has an excellent opportunity to provide international moral leadership in a new order for patenting. Although it is economically relatively small, Canada has considerable international moral authority, which it could wield in introducing considerations of values and ethics into patenting regimes. Canada needs to identify what is the right thing to do, and then consider how it can implement the identified actions within the existing limitations of treaties, obligations and national interests, rather than by starting from the present limitations and then considering what it can do. The discussion focused on three themes: a) Are there any inconsistencies in approach among Canada’s various international obligations? What are they? Why are they significant?Participants acknowledged that there were inconsistencies in the approach taken by trading partners with respect to patentability of biotechnology. Such inconsistencies included subject matter patentability, exemptions from infringement, and exclusions such as the “ordre public” and morality clauses. Most participants, however, favoured a “made-in-Canada” approach, with due regard to Canada’s international obligations. Inconsistencies among trading partners may be significant because Canada must compete in the international economy. Our own sovereignty and our ability to compete are influenced by many factors, including:
There appeared to be general agreement that Canada should develop positions on obligations presented by various treaties and agreements regarding patenting of higher life forms. These positions need not necessarily mean compliance and acceptance, but a clear articulation of a “made in Canada” policy. b) What actions, if any, should Canada take to address its international obligations regarding the patenting of higher life forms and related processes?Participants suggested that to the extent possible, harmonization of legislation, regulation and processes should be pursued between Canada and its trading partners. It was suggested that sufficient wiggle room exists within current international obligations for Canada. Many of the treaties and agreements provide for exemptions and exclusions; these should be assessed for application to Canada. A comprehensive biotechnology strategy that is uniquely Canadian is needed, that critically assesses what harmonization is in Canada’s best interests and what exemptions should be made. A preference emerged from the groups that an “ordre public” or morality clause should be developed that reflects the principles and values discussed in these consultations. Canada should also clearly state that human beings and other primates must not be patentable. Many participants felt that Canada could and should assume a leadership role in any future international agreements concerning the patenting of higher life forms specifically, and biotechnology in general. Some criticized the current treaties and agreements as biased in favour of trade and investment, with little regard for human rights and environmental matters. It was also noted that our major trading partners the US and the European Union take somewhat different approaches to the patenting of higher life forms. It was suggested that Canada assume a leadership role to ensure that future agreements fully consider and address human rights and environmental matters, as a balance to trade and investment. Specific actions could include:
c) Why are these actions necessary?Several reasons were provided supporting compliance with current obligations:
Not all participants stated the view that Canada must harmonize its patent process for higher life forms with its trading partners:
This session concluded that Canada’s present international stature should be the foundation for taking a leadership role in evolving to new international standards in the management of biotechnological innovation for the global good as well as in the interests of each nation, taking ethical and social values into full account. Please note that similar reports from each of the 5 CBAC roundtable consultations on Biotechnological Intellectual Property and the Patenting of Higher Life Forms, conducted across Canada from April 23 to May 4, 2001, will be posted on the CBAC website. As well, results from all 5 roundtables will be integrated into a single rollup report that will also be available on the CBAC website by the end of May 2001. Please visit the CBAC website at www.cbac-cccb.ca or call the CBAC toll-free number at 1-866-748-2222 for additional information or documents related to this or other CBAC projects. |
![]() |
![]() |
http://cbac-cccb.ca | ![]() |
|
![]() |
![]() |
![]() |
||
Created: 2005-07-13 Updated: 2006-06-30 ![]() |
![]() Top of Page ![]() |
Important Notices![]() |